- |||||||||| Emend intravenous (fosaprepitant) / Merck (MSD), Ono Pharma, Aloxi (palonosetron oral) / Helsinn, Otsuka, Roche, Eisai, Immedica
New P4 trial: Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer (clinicaltrials.gov) - May 3, 2023
P4, N=1028, Not yet recruiting,
- |||||||||| Review, Journal, CINV: Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting. (Pubmed Central) - Oct 18, 2018
To examine pharmacologic and clinical characteristics of neurokinin 1 (NK)-receptor antagonists (RAs) for preventing chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy, a literature search was performed for clinical studies in patients at risk of CINV with any approved NK RAs in the title or abstract: aprepitant (capsules or oral suspension), HTX019 (intravenous [IV] aprepitant), fosaprepitant (IV aprepitant prodrug), rolapitant (tablets or IV), and fixed-dose tablets combining netupitant or fosnetupi-tant (IV netupitant prodrug) with the 5-hydroxytryptamine type 3 (5HT) RA palonosetron (oral or IV)...Adding an NK RA to 5HT RA and dexamethasone significantly improves CINV control vs the two-drug regimen. Newer NK RAs offer more formulation options, higher acute-phase plasma levels, or improved tolerability, and increase clinicians' opportunities to maximize benefits of this important class of antiemetics.
- |||||||||| Journal: Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists. (Pubmed Central) - Oct 20, 2017
Aprepitant has not shown consistent superiority over a two-drug (ondansetron-dexamethasone) combination in nausea control after cisplatin- or anthracycline-cyclophosphamide (AC)-based highly emetogenic chemotherapy (HEC)...The potential impact of the new NK1RAs rolapitant and netupitant (oral fixed combination with palonosetron, as NEPA) in CIN prophylaxis is discussed...Recently, NK1RAs have been challenged by olanzapine, with olanzapine showing superior efficacy in nausea prevention after HEC. Fixed antiemetic combinations (such as NEPA) or new antiemetics with a long half-life that may be given once per chemotherapy cycle (rolapitant or NEPA) may improve patient compliance with antiemetic treatment.
- |||||||||| Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Aloxi (palonosetron oral) / Helsinn, Otsuka, Roche, Eisai
Journal: NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. (Pubmed Central) - Oct 13, 2017
Single-dose weekly PAL is a safe and tolerable antiemetic for cRINV prevention in MG patients receiving standard RT and concomitant TMZ. NEPA, a convenient, guideline-consistent, fixed antiemetic combination is effective and safe over multiple cycles of chemotherapy.
- |||||||||| Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Aloxi (palonosetron oral) / Helsinn, Otsuka, Roche, Eisai
Review, Journal: NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK. (Pubmed Central) - Apr 12, 2017
NEPA, a convenient, guideline-consistent, fixed antiemetic combination is effective and safe over multiple cycles of chemotherapy. Despite study limitations (study setting, time horizon, utility measure), the results suggest NEPA is cost effective for preventing CINV associated with HEC and MEC in the UK.
- |||||||||| Aloxi (palonosetron oral) / Helsinn, Otsuka, Roche, Eisai, Immedica
Trial completion: An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting (clinicaltrials.gov) - Jan 27, 2013
P3, N=743, Completed,
Despite study limitations (study setting, time horizon, utility measure), the results suggest NEPA is cost effective for preventing CINV associated with HEC and MEC in the UK. Recruiting --> Completed
|
